Basilea Pharmaceutica AG Share Price

Equities

BSLN

CH0011432447

Biotechnology & Medical Research

Market Closed - Swiss Exchange 16:31:30 26/04/2024 BST 5-day change 1st Jan Change
40.3 CHF +0.12% Intraday chart for Basilea Pharmaceutica AG -1.10% +14.16%

Financials

Sales 2024 * 182M 199M 15.92B Sales 2025 * 206M 225M 18.01B Capitalization 484M 529M 42.37B
Net income 2024 * 23M 25.15M 2.01B Net income 2025 * 35M 38.27M 3.07B EV / Sales 2024 * 2.98 x
Net Debt 2024 * 57.88M 63.29M 5.07B Net Debt 2025 * 12.51M 13.68M 1.1B EV / Sales 2025 * 2.41 x
P/E ratio 2024 *
20.2 x
P/E ratio 2025 *
17 x
Employees 147
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.55%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.12%
1 week-1.10%
Current month+7.04%
1 month+7.47%
3 months+16.81%
6 months+10.26%
Current year+14.16%
More quotes
1 week
40.25
Extreme 40.25
41.80
1 month
36.85
Extreme 36.85
44.65
Current year
32.00
Extreme 32
44.65
1 year
32.00
Extreme 32
49.00
3 years
29.55
Extreme 29.55
55.40
5 years
29.28
Extreme 29.28
61.95
10 years
29.28
Extreme 29.28
139.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 31/08/14
Director of Finance/CFO 50 31/12/08
Chief Tech/Sci/R&D Officer 60 30/04/18
Members of the board TitleAgeSince
Director/Board Member 71 26/04/17
Director/Board Member 66 31/12/21
Director/Board Member 69 08/04/13
More insiders
Date Price Change Volume
26/04/24 40.3 +0.12% 15,654
25/04/24 40.25 -0.74% 22,275
24/04/24 40.55 -1.70% 34,286
23/04/24 41.25 +0.86% 43,839
22/04/24 40.9 +0.37% 37,920

Delayed Quote Swiss Exchange, April 26, 2024 at 04:31 pm

More quotes
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
40.3 CHF
Average target price
70.58 CHF
Spread / Average Target
+75.14%
Consensus